Navigation Links
Majority of kidney cancers diagnosed at earliest stage
Date:5/18/2008

Patients in the United States today are now much more likely to be diagnosed with smaller tumors, in the earliest, most treatable stage of kidney cancer than a decade ago, leading to a slightly higher survival rate, according to the results of a national study led by a UC San Diego Medical Center researcher.

Christopher J. Kane, M.D., chief of urology at UC San Diego Medical Center and the Moores UCSD Cancer Center, and a team of researchers, analyzed records of more than 200,000 kidney cancer patients described in the National Cancer Data Base to look at how kidney cancer presentation has changed over a twelve-year period. The National Cancer Database is sponsored by the American College of Surgeons and the Joint Commission on Cancer and includes information from hospital tumor registries in the U.S. The study will be published online for the May 2008 edition of Cancer.

The changes in kidney cancer presentation are visible nationally and quite dramatic. If you are diagnosed with kidney cancer today, it is more likely to be at the earliest stage I level as opposed to more advanced stage II, III or IV just a decade ago, said Kane, a surgeon who specializes in treating kidney and prostate cancers. The study also reveals a small but significantly higher survival rate for recently diagnosed kidney cancers. This is good news for the more than 50,000 kidney cancer patients who will be identified this year.

The analysis looked at kidney cancer data between 1993 and 2004. Findings reveal that stage I kidney cancers increased from approximately 43% in 1993 to 57% in 2004, but decreased in stages II-IV of the disease. The average size of the stage I tumors decreased from 4.1 cm in 1993 to 3.6 cm in 2003. Overall survival for all patients with kidney cancer increased 3.3% between 1993 and 2003. The 5-year survival rate for people with stage I kidney cancer is now 88% or better.

While the reason for the downward trend is not known wi
'/>"/>

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care
2. New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support
3. 2008 Childrens Nutrition Survey Reveals Majority of U.S. Parents Unaware of DHA Benefits to Childrens Health
4. Former U.S. Senate Majority Leaders Baker, Daschle, Dole, and Mitchell Launch Unprecedented Health Care Effort
5. Medco Acquires Majority Interest in Europa Apotheek; Delivering Innovation, Clinical Quality and Lower-Cost Solutions to Fast-Growing German Health Care Market
6. Blunt: On PEPFAR, Majority Attempts to Spend in Five Years What CBO Says It Cant in 10
7. Majority of U.S. Doctors Back National Insurance Plan
8. Indiana University study finds majority of US physicians favor national health insurance
9. New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home
10. New National Poll: Majority of American Voters Oppose Bush Administrations Proposed Cuts to Medicare
11. Overwhelming Majority of Michigan Residents Favors Individual Health Insurance Market Reforms Supported by Blue Cross Blue Shield of Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...t therapy given during surgery extends survival ti...fe expectancy in non-small cell lung cancer (NSCLC...e is very hard to treat, especially when it has sp...ors at Thomas Jefferson University Hospital, Phila...
...rson aged 40 or over has a lifetime risk of heart ...ave high blood pressure. Heart failure is an incre...ed by increasing pressure within the heart which m...body. Typical symptoms are breathlessness and fati...
...prescribed medicines by the doctor are to be verif...ay an important role in helping you. Experts at th...t of your health care team, alongside your physici... your medications dispensed at the once pharmacy. ...
... coughs are harmless, while others merit medical a..., symptom. Most often it's part and parcel of a co...o spread the infection, there's little you can do....a more serious underlying medical condition. Doct...
Other Medicine News:
(Date:8/14/2008)...Newswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: ...mmitted to,discovering, developing and commerciali...ed unaudited financial results for the third fisca... a net loss attributable to,common stockholders of...he,quarter ended June 30, 2008, as compared to a n...
(Date:8/14/2008)...14 /- The Clinical Trials,Bootcamp an...hysicians,clinical coordinators, clinical researc...It will be held in Boca Raton at the Boca Resort f...inical coordinators, monitors and,other industry p...orporate,clinical trials into a practice, as well ...
(Date:8/14/2008)...begin in late 2008 or in early 2009 -, SAN CARLOS..., Inc.,(Nasdaq: NUVO ) today announced positive r... NU172, demonstrating that the direct thrombin,inh...tion with a rapid,return toward baseline after the... "NU172 has the potential to address many of the l...
(Date:8/13/2008)...-FirstCall/ -- As biotechnology,pharmaceutical an...cal,trials beyond their own borders to other parts...uth America, complicated regulatory environments,c...rding to an analysis by,Aon Corporation (NYSE: AO...those companies a visual representation of the com...
Breaking Medicine Technology:Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 2Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 3Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 4Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 5Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 6Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 7Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 8Pharmasset Reports Financial Results for Quarter Ended June 30, 2008 9Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 1Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 2Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 3Consumers Health Care Purchasers Applaud Agreement On Physician Performance Reporting 4851 4Dead clams tell many tales 1007 1Dead clams tell many tales 1007 2Dead clams tell many tales 1007 3Dead clams tell many tales 1007 4Tiny radioactive spheres effectively treat cancer that has spread to the liver 4844 1Tiny radioactive spheres effectively treat cancer that has spread to the liver 4844 2New treatment option studied for bladder cancer 4839 1New treatment option studied for bladder cancer 4839 2New treatment option studied for bladder cancer 4839 3
..., Calif., May 02, 2007 /PRNewswire/ -- Ceregene, I...hase 1 trial of,CERE-110, a gene therapy product d...he treatment of Alzheimer,s disease. After one,yea...ho received,CERE-110 in the trial indicate that a ...rated, and an interim analysis suggested that,the ...
...Y, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data ha...sclerosis (RRMS),patients treated with COPAXONE(R)...munosuppression with mitoxantrone experienced a,90...MRI)-monitored,disease activity compared to their ...d were sustained throughout the 24-month study,per...
Other Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...
Medicine Products: